Investigating how FGL1 affects tumor immunity and developing new cancer immunotherapy
Elucidating the Role of Cancer-Associated FGL1 in Tumor Immunity and Developing FGL1-Guided Anti-LAG-3 Cancer Immunotherapy
This study is looking at a protein called FGL1 and how it affects the immune system's ability to fight cancer, with the hope of finding new ways to boost cancer treatments for patients.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10870154 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of fibrinogen-like protein 1 (FGL1) in tumor immunity and its potential as a target for cancer immunotherapy. The study explores how FGL1 interacts with the LAG-3 receptor on T-cells, which may inhibit the immune response against tumors. By blocking this interaction, the researchers aim to enhance the effectiveness of existing cancer treatments. Patients may benefit from new therapies that improve immune responses against their tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who have shown resistance to current immune checkpoint therapies.
Not a fit: Patients who do not have cancer or those whose tumors do not express LAG-3 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer immunotherapies that enhance the body's ability to fight tumors.
How similar studies have performed: Other research has shown promising results with similar approaches targeting immune checkpoints, indicating potential for success in this area.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Wang, Jun — New York University School of Medicine
- Study coordinator: Wang, Jun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.